CAZ104
CAZ104 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
1 source entries across 1 studies. This list may not include all unresolved or historical entries.
- CAZ104Registry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
0
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma
A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
Clinical Trials (3)
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma
A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
All 3 trials loaded
Drug Details
- Intervention Type
- Drug
- Total Trials
- 3